BioToxTech Co

BioToxTech Co R&D Expenses

The Research & Development Expenses of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 642.58 M KRW. In the previous year, Research & Development Expenses was 694.43 M KRW — a change of -7.47% (lower).

R&D Expenses

642.58 MKRW

YoY

-7.47%

Last updated:

Research & Development Expenses of BioToxTech Co is 2025 642.58 M KRW. Research & Development Expenses of BioToxTech Co was 2024 694.43 M KRW. It decreases by -7.47% lower compared to the previous year.

The BioToxTech Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2014
1.11 B KRW
Jan 1, 2015
23.30 M KRW
Jan 1, 2016
82.80 M KRW
Jan 1, 2017
82.80 M KRW
Jan 1, 2018
202.63 M KRW
Jan 1, 2023
453.68 M KRW
Jan 1, 2024
694.43 M KRW
Jan 1, 2025
642.58 M KRW
The BioToxTech Co R&D Expenses history
YEARR&D ExpensesYoY
642.58 MKRW-7.47%
694.43 MKRW+53.07%
453.68 MKRW+123.89%
202.63 MKRW+144.72%
82.80 MKRW0.00%
82.80 MKRW+255.37%
23.30 MKRW-97.91%
1.11 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Research & Development Expenses of BioToxTech Co is 642.58 M KRW in 2025.

Research & Development Expenses of BioToxTech Co changed from 694.43 M KRW to 642.58 M KRW, representing a -7.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioToxTech Co

All Key Metrics — BioToxTech Co